Bruker appoints QIAGEN CEO Thierry Bernard to Board of Directors

BRUKER CORP

Thierry L. Bernard appointed to Bruker's Board effective April 1, 2026; board expanded to 12 directors.
Bernard is CEO of QIAGEN N.V. (NYSE: QGEN), set to step down upon successor appointment; brings life-science tools expertise.
He previously served 15 years at bioMérieux including Corporate VP Global Commercial Operations, Investor Relations, and Greater China.
Bernard also sits on Neogen Corporation (NASDAQ: NEOG) board and chairs AdvaMedDx trade association.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.